Uncategorized
Glaukos completes patient enrollment in iDose phase 2 trial
Patient enrollment in the phase 2 clinical trial of the iDose travoprost intraocular implant for glaucoma patients has been completed, Glaukos announced in a press release.The 150-patient, multicenter, randomized, double-masked phase 2 trial will study two forms of the iDose delivery system with different elution rates against topical timolol maleate ophthalmic solution 0.5%, the release said. The investigational new drug study will evaluate the safety and efficacy of lowering IOP in patients with open-angle glaucoma and will be unmasked after 12 weeks of follow-up.